Communiqués Mirum Pharmaceuticals, Inc.

Actions

MIRM

US6047491013

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 05/10/2026			Varia. 5j.	Varia. 1 janv.
81,43 ^USD	-1,81%		-7,42%	+3,09%

02/10	Le S&P 500 en léger repli hebdomadaire, pénalisé par la santé et les services financiers	MT
28/09	Transcript : Mirum Pharmaceuticals, Inc. - Special Call

Communiqués

29/09	Mirum Pharmaceuticals annonce que le critère d’évaluation principal a été atteint dans l’étude de phase III AZURE-1 portant sur le brelovitug dans le traitement de l’infection chronique par le virus de l’hépatite D (VHD)	BU
28/09	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus	BU
27/09	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026	BU
26/09	Mirum Pharmaceuticals et Incyte annoncent l’autorisation par la FDA américaine d’Atebrioz™ (zilurgisertib) pour les patients adultes et pédiatriques atteints de fibrodysplasie ossifiante progressive	BU
26/09	Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva	BU
14/09	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
08/09	Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer	BU
02/09	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences	BU
11/08	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05/08	Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update	BU
29/07	Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026	BU
14/07	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 13, 2026	AQ
13/07	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
14/06	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva	BU
11/06	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
04/06	Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026	BU
30/05	Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026	BU
21/05	Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026	BU
14/05	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
13/05	Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes	BU
12/05	Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering	BU
12/05	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences	BU
06/05	Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update	BU
04/05	Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis	BU
03/05	Mirum Pharmaceuticals : to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026	PU